
FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
Hub vendor transitions are accelerating. A 2026 Cardinal Health survey of 200 biopharma executives found that 45% are considering consolidating hub vendors by 2028, and 39% have felt pressure to move hub functions in-house, up from 28% in 2024.






